Accordingly, we focused our study on the active components of C. maackii (Figure 1) as dietary supplements for treating T2D and AD through the inhibition of the α-glucosidase and BACE1 enzymes, respectively. The gene discussed is BACE1; the disease is type 2 diabetes mellitus.